• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EU Paper Tasks Sponsors, Investigators with Oversight of Decentralized Trial Data

EU Paper Tasks Sponsors, Investigators with Oversight of Decentralized Trial Data

December 19, 2022

In trials using decentralized elements, sponsors and investigators have ultimate responsibility for ensuring the integrity of the data generated, says a draft EU guideline, placing additional oversight duties on their plates.

The release of the paper by the European Medicines Agency (EMA), European Commission and Heads of Medicines Agencies comes at a time when researchers have expressed concern about regulatory barriers to decentralized trials (DCT) (CenterWatch Weekly, Dec. 12).

“Introducing decentralized elements should be considered as an extension of the … site with the inclusion of the trial participants’ home, resulting in an additional obligation of oversight for investigators and sponsors,” the draft says.

“The protocol should reflect that the sponsor and the investigator are in full control of their respective areas of responsibilities at all times, e.g., with respect to the data processing, the communication flow and, ultimately, the rights, safety, dignity and well-being of the trial participants and reliability of the trial data,” the paper reads.

For example, sponsors and investigators should ensure the assignment of activities to different parties is well defined whenever a DCT methodology is introduced. Clearly document which tasks are done when, by whom and in which setting, such as at the trial site or the patients’ homes, as well as how the required oversight by the sponsor or investigator will be achieved. An overview of the workflow for these tasks should be laid out generally in the protocol and in greater detail in a protocol-related document, the guidance says.

In addition, trial-specific activities shopped out to a service provider should be specified in a written agreement between the responsible party (as directed in ICH E6) and the provider.

When a sponsor chooses a provider and the investigator is not involved in the agreement, the contract between the sponsor and investigator should clearly document that agreement between the sponsor and service provider when it relates to tasks under the investigator’s responsibility, the guidance says. By doing this, the investigator can agree or disagree to the use of service providers for medical care-related trial tasks.

The guidance also offers the EMA’s perspective on informed consent in DCTs, the delivery and administration of investigational products at home, the conduct of trial-related procedures at home, data collection and management, and trial monitoring.

Read the full draft guidance here: https://bit.ly/3hDQLau.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing